<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G/A
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)*
CALYPTE BIOMEDICAL CORPORATION
------------------------------
(Name of Issuer)
COMMON STOCK
------------
(Title of Class of Securities)
0000899426
----------
(CUSIP Number)
The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this coverage page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of the
Act (however, see the Notes).
Page 1 of 4 pages
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 0000899426 13G PAGE 2 OF 4 PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
NAME OF REPORTING PERSON
1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Otsuka Parmaceutical Co. Ltd.
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [_]
(b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
4
Japan
- ------------------------------------------------------------------------------
SOLE VOTING POWER
5
NUMBER OF 1,293,147
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 6
N/A
OWNED BY
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
7
REPORTING 1,293,147
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 8
N/A
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9
1,293,147
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
10
N/A
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11
9.8%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
12
CO
- ------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
Page 3 of 4
Item 1(a): NAME OF ISSUER
Calypte Biomedical Corporation
Item 1(b): ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
1440 Fourth Street
Berkeley, CA 94710
Item 2(a): NAME OF PERSON FILING
Otsuka Pharmaceutical Co. Ltd.
Item 2(b): ADDRESS OF PRINCIPAL BUSINESS OFFICE
463-10 Kagasuno, Kawauchi-cho, Tokushima 771-01 Japan
Item 2(c): CITIZENSHIP
Japan
Item 2(d): TITLE OF CLASS OF SECURITIES
Common Stock
Item 2(e): CUSIP NUMBER
000899426
Item 3: This statement is not filed pursuant to Rules 13d-1(b) or 13d-2, and
therefore this item is not applicable.
Item 4: OWNERSHIP
(a) Amount Beneficially Owned:
1,293,147 shares
(b) Percent of Class
9.8%
(c) Number of Shares as to Which Such Person Has:
(i) sole power to vote or direct the vote:
1,293,147 Shares
(ii) Shared power to vote or direct the vote:
0 Shares
<PAGE>
Page 4 of 4
(iii) Sole power to dispose or to direct the disposition of:
1,293,147 Shares
(iv) Shared power to dispose or to direct the disposition of:
0 Shares
Item 5: OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
N/A
Item 6: OWNERSHIP OF NOT MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
N/A
Item 7: IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE
SECURITY BEING REPORTED BY THE PARENT HOLDING COMPANY
N/A
Item 8: IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
N/A
Item 9: NOTICE OF DISSOLUTION OF GROUP
N/A
Item 10: CERTIFICATION
N/A
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
February 17, 1998
- ------------------------------
Date
Otsuka Pharmaceutical Co. Ltd.
/s/ HIDEJI NONOMURA
- ------------------------------
Hideji Nonomura, Director, Department of Diagnosis
